Skip to contentC
Cannabis Bioscience International Holdings, Inc.
C
CBIHCannabis Bioscience International Holdings, Inc. Q3 2024 · 10-Q
Revenue$36.41K$36.41K−29.0% vs Q3 2023 Net Income-$209.19K-$209.19KN/M vs Q3 2023 EPS Diluted-$0.00-$0.00N/M vs Q3 2023 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Cannabis Bioscience International Holdings, Inc. · CIK 1411057 · Engraved from SEC EDGAR
Operating Cash Flowderived-$9,076N/M Margins · derivedGross margin67.6%+14.6 pt vs Q3 2023
Operating margin-439.3%+116.5 pt vs Q3 2023
Net margin-574.5%+58.9 pt vs Q3 2023
ended Feb 29, 2024 · filed Apr 22, 2024 · 53 d after period end